225 related articles for article (PubMed ID: 6130534)
21. Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder.
Marcus SC; Durkin M
J Am Acad Child Adolesc Psychiatry; 2011 May; 50(5):480-9. PubMed ID: 21515197
[TBL] [Abstract][Full Text] [Related]
22. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
Bricard C; Boidein F
Encephale; 2001; 27(5):435-43. PubMed ID: 11760693
[TBL] [Abstract][Full Text] [Related]
23. [Basics of the drug therapy for attention deficit hyperactivity disorders in adolescents].
Airaksinen E; Airaksinen MM
Duodecim; 2003; 119(16):1553-62. PubMed ID: 14535028
[No Abstract] [Full Text] [Related]
24. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
Knight M
Pediatrics; 2007 Jan; 119(1):154-5. PubMed ID: 17200281
[No Abstract] [Full Text] [Related]
25. Pemoline (Cylert) for minimal brain dysfunction.
Med Lett Drugs Ther; 1976 Jan; 18(2):5-6. PubMed ID: 1107790
[No Abstract] [Full Text] [Related]
26. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
Stasik D; Tucha O; Tucha L; Walitza S; Lange KW
Psychiatr Pol; 2009; 43(2):183-92. PubMed ID: 19697788
[TBL] [Abstract][Full Text] [Related]
27. American Academy of Pediatrics Committee on Children with Disabilities, Committee on Drugs: Medication for children with an attention deficit disorder.
Pediatrics; 1987 Nov; 80(5):758-60. PubMed ID: 3670981
[No Abstract] [Full Text] [Related]
28. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder.
Castellanos FX; Elia J; Kruesi MJ; Marsh WL; Gulotta CS; Potter WZ; Ritchie GF; Hamburger SD; Rapoport JL
Neuropsychopharmacology; 1996 Feb; 14(2):125-37. PubMed ID: 8822535
[TBL] [Abstract][Full Text] [Related]
29. Clinical practice. Attention deficit-hyperactivity disorder.
Rappley MD
N Engl J Med; 2005 Jan; 352(2):165-73. PubMed ID: 15647579
[No Abstract] [Full Text] [Related]
30. [Methylphenidate (Ritalin) treatment in attention deficit hyperactivity disorder].
Shalev R; Gross-Tsur V
Harefuah; 1997 May; 132(9):672-5. PubMed ID: 9225587
[No Abstract] [Full Text] [Related]
31. Increased urine phenylethylamine after methylphenidate treatment in children with ADHD.
Kusaga A; Yamashita Y; Koeda T; Hiratani M; Kaneko M; Yamada S; Matsuishi T
Ann Neurol; 2002 Sep; 52(3):372-4. PubMed ID: 12205654
[TBL] [Abstract][Full Text] [Related]
32. Stimulant treatment of adult attention-deficit/hyperactivity disorder.
Spencer T; Biederman J; Wilens T
Psychiatr Clin North Am; 2004 Jun; 27(2):361-72. PubMed ID: 15064002
[TBL] [Abstract][Full Text] [Related]
33. Pemoline in ADHD.
Winsberg B; Barbato M
J Am Acad Child Adolesc Psychiatry; 1997 Dec; 36(12):1649-50. PubMed ID: 9401321
[No Abstract] [Full Text] [Related]
34. Influence of stimulants on electrodermal studies in Fragile X syndrome.
Hagerman RJ; Miller LJ; McGrath-Clarke J; Riley K; Goldson E; Harris SW; Simon J; Church K; Bonnell J; Ognibene TC; McIntosh DN
Microsc Res Tech; 2002 May; 57(3):168-73. PubMed ID: 12112453
[TBL] [Abstract][Full Text] [Related]
35. Medication for children with attention disorders.
Kash IJ
Pediatrics; 1997 Jun; 99(6):922-3. PubMed ID: 9164792
[No Abstract] [Full Text] [Related]
36. Compliance with FDA recommendations for pemoline.
Sarkis EH
J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):383; author reply 383. PubMed ID: 12649623
[No Abstract] [Full Text] [Related]
37. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
[TBL] [Abstract][Full Text] [Related]
38. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
[No Abstract] [Full Text] [Related]
39. Reduced salivary cortisol in children with comorbid Attention deficit hyperactivity disorder and oppositional defiant disorder.
Kariyawasam SH; Zaw F; Handley SL
Neuro Endocrinol Lett; 2002 Feb; 23(1):45-8. PubMed ID: 11880861
[TBL] [Abstract][Full Text] [Related]
40. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
